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Abstract 
 
Background: The long-term effects of probiotic intervention for primary prevention of allergic 
diseases are not well known. We previously reported less eczema until 10 years in our probiotic 
intervention trial. 
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Objective: To investigate the effect of early probiotic intervention on the prevalence of allergic 
diseases up to 13 years of age. 
 
Methods: Pregnant women (n=1223) carrying a child at a high risk of allergy (at least one parent with 
allergic disease) were randomised to receive a mixture of probiotics (Lactobacillus rhamnosus GG 
and LC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii) or placebo in a 
double-blind manner from 36 weeks of gestation until birth. Their infants received the same product 
for the first six months (registration number NCT00298337). At 13-year follow-up the participants 
were requested to return a questionnaire and to provide a blood sample. 
 
Results: A questionnaire was returned by 642 participants (63.1% of intention-to-treat infants) and 
459 provided a blood sample. In the whole cohort there were no statistically significant differences 
in doctor-diagnosed allergic disease (55.2% and 59.0%, probiotic and placebo group, respectively) or 
allergic disease (47.9% and 51.6%) based on the ISAAC questionnaire data. Inhalant-specific IgE-
sensitisation (>0.7 kU/L) was 59.3% in the probiotic group and 49.8% in the placebo group (p=0.040). 
In a post hoc analysis made in Caesarean-delivered subgroup allergy was reported in 41.5% of the 
probiotic group and 67.9% of the placebo group (p=0.006), and eczema in 18.9% and 37.5% 
respectively (p=0.031). In the whole cohort 8.5% of the probiotic group had suffered from wheezing 
attacks during the previous 12 months vs. 14.7% in the placebo group (p=0.013). There was no 
statistically significant differences discovered between the characteristics of the participating group 
and the dropout-group. 
 
Conclusions: Probiotic intervention protected Caesarean-delivered subgroup from allergic disease 
and eczema, but not the total cohort. 
 
Introduction 
The prevalence of allergic disease has increased and is especially a burden for the child population 
(1). The increase in prevalence is connected to westernization and is believed to be connected to 
decreased microbial exposure. Living on a farm (2), and consuming farm milk (3) has been linked to 
fewer allergic diseases, which might be associated with greater microbial exposure. Birth via 
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Caesarean section is connected to higher risk of asthma (4,5). A connection between early-life 
microbiota composition and atopy has been reported (6,7), and non-allergic children’s microflora 
has been shown to be more diverse (8). The presence of probiotic bacteria in the intestinal 
microflora during the first year of life is connected to less allergic morbidity up to two years of age 
(9). 
  
Probiotics are defined as 'live microorganisms which when administered in adequate amounts, 
confer a health benefit on the host' (Food and Agricultural Organisation). In a large observational 
cohort study of over 40 000 participants, consumption of probiotic milk products in pregnancy and 
infancy was associated with a slightly reduced risk of atopic eczema at six months and reduced 
rhinoconjunctivitis at 18 to 36 months. There was no association with asthma. The information 
about the probiotic usage was based on self-report. The probiotics used were three dairy products, 
Biola milk, Biola yogurt and Cultura milk (10), which contained L. acidophilus (LA-5). 
 
It has been shown in several studies that probiotics given pre- and postnatally prevent eczema for 
up to two years of age (11–13). In longer 6-year follow-up studies an allergy-reducing effect has 
been reported in some (14,15) but not all studies (16). Kalliomäki et al. reported less atopic eczema 
for up to seven years (17). Other 7- to 8-year follow-up studies have shown no effect (18,19). In 
previous phases of our study, the largest probiotic intervention trial reported to date, we found 29% 
less atopic disease at two years of age in the group receiving probiotics in the perinatal period (20). 
In the 5-year follow-up there was no statistically significant difference in the whole cohort, but the 
Caesarean-delivered children in the probiotic group had significantly less IgE-associated allergy (21). 
At 10 years of age the reducing effect on eczema was still visible and, surprisingly, allergic 
rhinoconjunctivitis was increased at 5–10 years (22) . The objective of this follow-up was to 
investigate the effect of perinatal probiotic intervention on the prevalence of allergic diseases and 
sensitisation at 13-years of age. 
 
Methods 
Pregnant women carrying a child at a high risk of allergy were recruited for the trial. The criterion for 
high allergy risk was that at least one of the parents had had doctor-diagnosed asthma, allergic 
rhinitis, or atopic eczema. The participants (n=1223) were randomised to receive a preparation of 
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four probiotics or placebo in a double-blind manner (Chart 1). Starting from 36 weeks of gestation 
mothers in the probiotic group received one capsule containing freeze-dried LGG (American Type 
Culture Collection 53103; 5 × 109 colony-forming units (CFU)), L. rhamnosus LC705 (DSM 7061; 5 × 
109 CFU), Bifidobacterium breve Bb99 (DSM 13692; 2 × 108 CFU) and Propionibacterium 
freudenreichii ssp. shermanii JS (DSM 7076; 2 × 109 CFU) twice a day until delivery. Their infants 
received the same probiotic capsule opened and mixed with 20 drops of syrup containing 0.8 g of 
galacto-oligosaccharides once daily for the first six months of their life. 
 
Mothers in the placebo group received capsules containing microcrystalline cellulose, and the 
infants received the contents of the same capsules, with no oligosaccharides. The capsules and 
syrups used in the trial looked, smelled and tasted identical. The viability of the bacteria was 
regularly controlled. Use of non-study probiotic products (Table 2) was not restricted after the 
intervention phase. Exclusion criteria were birth at less than 37 weeks of gestation, major 
malformations and the second-born of twins. 
 
Compliance with the intervention was controlled at 3- and 6-month visits by questioning about the 
amount of doses not given and by counting the returned unused capsules. The 80% compliance level 
for the 180 days intervention was reached by 87% in the probiotic group and 88% in the placebo 
group. During their early years, the children were examined by a paediatrician at six months, two 
and five years and questionnaires concerning symptoms of allergic or infectious disease and related 
environmental factors were assessed annually up to five years (20). After the 5-year visit the 
participants parents and study staff were unblinded. 
 
This 13-year follow-up study was carried out in 2013–15. A total of 945 previously reachable and 
willing participants received a letter asking them to complete a questionnaire on allergy, probiotic 
use and environmental factors. In the questionnaire we asked if the participants had had doctor-
diagnosed eczema, asthma, rhinitis or food allergy, and there were more detailed questions about 
the symptoms, giving us more specific information on allergic morbidity in the preceding time, 
especially the previous 12 months. This questionnaire was based on the Finnish version of the 
International Study of Asthma and Allergies in Childhood (ISAAC) Questionnaire for 13- to 14-year-
old children (23,24). The questionnaire includes questions about wheezing and coughing, sneezing, a 
runny or blocked nose, and eczema symptoms. Participants were asked to report the frequency of 
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wheezing attacks over the past 12 months and the frequency of night wheezing in the questionnaire 
(Section 7.2 in the original questionnaire (25)). For the purpose of these analyses, wheezing attacks 
was dichotomised as "no attacks" and "one or more attacks" in the past 12 months.  Night wheezing 
was dichotomised as “Less than one night a week” and “One or more nights per week”. Our research 
is not part of the ISAAC collaboration. 
 
The primary outcome variable was doctor-diagnosed allergic disease (eczema, asthma, rhinitis, food 
allergy). A combination of questionnaire answers was used to define the presence of allergic illness 
during the previous 12 months. A symptom-report-based diagnosis of eczema was made if three 
specific questions were answered affirmatively, i.e. "Have you ever had an itchy rash which was 
coming and going for at least six months?", "Has this itchy rash at any time affected any of the 
following places: the folds of the elbows, behind the knees, the front of the ankles, under the 
buttocks, or around the neck, ears, or eyes?" and "Have you had this itchy rash at any time in the 
past 12 months?". The child was considered to have had allergic rhinitis if the three following 
questions were answered affirmatively: "Have you ever had a problem with sneezing, or a runny or 
blocked nose when you DID NOT have a cold or the flu?", "In the past 12 months have you had a 
problem with sneezing, or a runny or blocked nose when you DID NOT have a cold or the flu?" and 
"In the past 12 months has this nose problem been accompanied by itchy-watery eyes?". The child 
was considered to have asthma if the two following questions were answered affirmatively: "Have 
you had wheezing or whistling in the chest in the past 12 months?" and "Have you ever had 
asthma?" Additionally, we recorded allergic disease combined with a serum antigen-specific IgE level 
of >0.7 kU/L. In the context of eczema and asthma, all specific IgE levels are considered. With 
rhinitis, only inhalant-specific IgE levels are considered, and with food allergy, only food-specific IgE 
levels are considered. 
 
The participants were requested to come for appointment with research nurse, were blood samples 
were drawn to investigate IgE sensitisation status and to check essential haematological values for 
safety assessment of the probiotic intervention. Specific IgE antibodies were analysed – against 
birch, timothy grass, mugwort, cat dander, dog dander, house dust mites, egg white, milk and 
peanuts. Analysis was carried out using an ImmunoCAP system (Thermo Fisher Scientific Inc, 
Waltham, MA, USA). Haematological values analysed were haemoglobin concentration, red-blood 
cell indices and leucocyte and platelet counts. The research nurse also assessed the participants 
eczema using the SCORAD (SCORing Atopic Dermatitis) and measured height and weight. 
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In a subgroup (n=296), peak expiratory flow (PEF) measurements were carried out to evaluate 
respiratory function. All participants were tested three times with reasonable resting time in 
between. Measurements were carried out with a hand-held Pinnacle Peak Flow Meter (Fyne 
Dynamics Ltd, Harlow, UK). 
 
Pearson’s chi-squared test was used to compare categorical variables. Continuous variables were 
compared with t-tests. An exploratory analysis was carried out to assess the effects of other 
potential predictive factors. These factors included sex, biparental atopy, mode of delivery, number 
of siblings, duration of total and exclusive breast feeding, parental education, smoking at home, 
household pets, antibiotic treatment during the intervention period and regular use of other 
probiotic preparations. The status of these factors was based on information gathered at 0 –2 years 
of age.  Smoking at home and household pets were also considered at 13 years of age. Use of non-
study probiotic preparations was considered at 0–2, 3–5 and 13 years. Interactions between the 
above predictive factors and the intervention were first assessed by using the Breslow–Day test. 
Doctor-diagnosed allergic disease, doctor-diagnosed allergic disease with sensitisation, ISAAC-based 
allergic disease and ISAAC-based allergic disease with sensitisation were used as an outcome 
variables for that analysis. Stratified analyses were subsequently performed for mode of delivery as 
statistically significant interactions were found between mode of delivery and these four outcomes 
(p-values for interactions were 0.860, 0.187, 0.009 and 0.025, respectively). Holm method was used 
to adjust for multiple comparisons. A separate analysis with missing values imputed from 10-year 
follow-up was also performed. All data analysis was carried out using IBM-SPSS software version 
24. The Ethics Committee of the Hospital for Children and Adolescents at Helsinki University Hospital 
approved the study. The clinical trials registration number for the trial is NCT00298337. There is no 
separate registration for the 13-year follow-up. 
 
Results 
In the initial phase of the study, there were 1018 intention-to-treat infants. A total of 642 
participants (63.1%) completed the questionnaire at the 13-year follow-up, with 330 children from 
the probiotic group and 312 from the placebo group. The demographic characteristics of the groups 
were similar (Table 1). Among those who provided a blood sample (n = 459), 43.7 % had a household 
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dog or cat at 13 years of age, compared to 32.9 % of the subgroup who did not provide a blood 
sample (p=0.010). There was no other significant differences between these two groups 
(Appendices, Table 6). In vaginally delivered subgroup 73.4% were breastfed for six months or more, 
compared to 63.3% in caesarean delivered subgroup (p=0.036). Mothers average age was 31.07 
years in vaginally delivered and 32.57 years in caesarean delivered group (p=0.002). No other 
variables had significant differences between these two groups (Appendices, Table 6). Participants of 
the 13-year follow-up were compared to others in the intention-to-treat group. Infants, who 
dropped out in the early phase (64) had to be ignored in the analysis due to missing data. The others 
had no significant differences in the available variables compared to participants of the 13-year 
follow-up (Appendices, Table 6). The average age at the day of attending the study was 12.9 years, 
with only a 7-day difference between the probiotic and placebo groups. The prevalence of allergic 
disease at five years of age did not differ significantly between the cohort participating in the 13-
year follow-up and those who did not participate (data not shown). 
 
At 0–2 and 3–5 years of age the continuous consumption of non-study probiotics did not differ 
significantly between the probiotic and placebo groups (Table 2). In the 13-year follow-up, there was 
no significant difference in daily use of probiotics between the groups (9.7% in the probiotic group 
and 6.7% in the placebo group, p=0.172), but more participants in the probiotic group reported 
using probiotics weekly (16.1% vs. 10.6%, p=0.041) during the previous 12 months. These non-study 
products contained mainly Lactobacillus rhamnosus GG or Lactobacillus reuteri. 
 
Among the primary clinical outcomes (Table 3), no statistically significant differences were found in 
the prevalence rates of doctor-diagnosed allergic disease (55.2% in the probiotic group and 59.0% in 
the placebo group, p=0.328) or any allergic disease with IgE sensitisation (42.7% and 39.9%, 
p=0.547). Regarding the secondary clinical outcomes (Table 3), no statistically significant differences 
between the groups were found in the prevalence rates of doctor-diagnosed asthma (12.7% and 
17.0%, p=0.129), eczema (31.8% and 35.6%, p=0.314), food allergy (22.7% and 26.9%, p=0.218) or 
food-specific sensitisation (21.5% and 19.2%, p=0.543). However, the presence of inhalant-specific 
IgE-sensitisation (>0.7 kU/L) was 59.3% in the probiotic group and 49.8% in the placebo group 
(p=0.040). There were no differences in the prevalence rates of individual allergic diseases as 
assessed by use of the ISAAC questionnaire (Table 3). 
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No significant differences between the probiotic and placebo groups were found as regards specific 
sensitisation to birch, timothy grass, mugwort, cat dander, dog dander, egg white, milk or peanuts 
(data not shown). The presence of a specific IgE to house dust mite was significantly lower in the 
probiotic group than in the placebo group (5.3% vs. 10.3%) at a >0.35 kU IgE/L level (Pearson’s test, 
p=0.042 and Fisher’s test, p=0.052). There was no difference at a >0.70 kU/L level (3.3% in the 
probiotic group and 5.6% in the placebo group, Pearson’s test, p=0.213 and Fisher’s test, p=0.255). 
 
Among the primary clinical outcomes in the Caesarean-delivered subgroup (n=109), there were no 
significant differences in the lifetime prevalence rates of any doctor-diagnosed allergic disease 
(64.2% and 66.1%, p=0.833), nor any allergic disease with IgE sensitisation (39.5% and 50.0%, 
p=0.350) (Table 4). Regarding secondary clinical outcomes there were no statistically significant 
differences in doctor-diagnosed individual allergic diseases. The prevalence of any allergic disease in 
the previous 12 months (ISAAC) was 41.5% in the probiotic group and 67.9% in the placebo group 
(p=0.006). On the basis of responses to ISAAC questions, the prevalence of current eczema was less 
common in the probiotic group (18.9%) than in the placebo group (37.5%) (p=0.031). There were no 
significant differences in sensitisation between the probiotic and placebo groups. 
 
Doctor-diagnosed allergic disease, doctor-diagnosed allergic disease with sensitisation, ISAAC-based 
allergic disease and ISAAC-based allergic disease with sensitisation for whole cohort and caesarean 
delivered subgroup are considered as the main outcome variables of the study. For the p-values of 
these 8 outcomes, Holm method was applied, and the difference in ISAAC-based allergic disease in 
caesarean delivered subgroup is considered significant. When the same analysis is applied on all p-
values on tables 3 and 4, none of them are significant. 
 
We also carried out an additional analysis for the primary and secondary clinical outcomes, where 
missing values where imputed from 10-year follow-up. Sensitisation was not analysed at 10-year 
follow-up, and sensitisation-related outcomes could not therefore be included in this analysis. There 
was no statistically significant results in the whole cohort (n=838). In the caesarean-delivered 
subgroup (n=144) the prevalence of any allergic disease in 12 months (ISAAC) was 44.1% in probiotic 
group and 61.8% in placebo group (p=0.033). There was no other significant differences.  
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Although the prevalence of asthma did not differ significantly in the whole cohort or in the 
aforementioned subgroups, wheezing attacks during the previous 12 months were reported by 8.5% 
of the probiotic group and 14.7% of the placebo group. A breakdown of the responses to asthma-
related ISAAC questions is presented in Table 5. Wheezing attacks during the previous 12 months 
represented the only variable with a significant difference. 
 
There was no significant difference in average SCORAD scores in the whole cohort (n=470, 1.94 in 
the probiotic group and 2.33 in the placebo group, p = 0.214) or in the caesarean delivered subgroup 
(n=79, 2.26 in the probiotic group and 2.17 in the placebo group, p = 0.701). In the whole cohort 
13.5% of the participants in the probiotic group and 17.4% of the participants of the placebo group 
had SCORAD higher than 0 (p=0.253). In the caesaren delivered subgroup 13.5% of the probiotic 
group and 19.0% of the placebo group had SCORAD higher than 0 (p=0.508). 
 
Growth was similar in the two groups (Appendices, Table 7). Essential haematological values were 
normal in the study population, and there were no statistically significant differences between the 
groups (Appendices, Table 8). There were no statistically significant differences in PEF 
measurements. The average PEF result was 356 L/min in the probiotic group (n=153) and 359 L/min 
(n=143) in the placebo group. For boys, the average PEF result was 360 L/min in the probiotic group 
and 370 L/min in the placebo group. For girls, the average PEF result was 351 L/min in the probiotic 
group and 348 L/min in the placebo group. The average best PEF result of three was 359 L/min in the 
probiotic group and 364 L/min in the placebo group. 
 
Discussion 
Early probiotic treatment did not show an overall preventive effect on doctor-diagnosed allergic 
diseases in 13-year follow-up. However, in the Caesarean-delivered subgroup a statistically 
significant effect was observed in the incidence of any allergy, and eczema, as reported in the ISAAC 
questionnaire. Analysis of the caesarean delivered subgroup was not preplanned in the original 
study protocol. It should also be noted, that in this study design the birth-mode is a post-
randomisation variable. There was no significant difference in SCORAD scores between probiotic and 
placebo groups. An important motivation behind this follow-up study was to investigate the possible 
effect of probiotic treatment on airway allergies, which mostly become manifest in later childhood. 
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The probiotic group reported clearly fewer wheezing attacks in the previous 12 months, but this was 
not reflected in the overall prevalence of asthma or allergic rhinitis, or in PEF measurements. Unlike 
it was done in the 2- and 5-year follow-up, this follow-up did not include clinical evaluation by 
pediatrician, but children met a study nurse. The limitations of questionnaire-reported assessment 
has to be taken into an account. 
 
We have reported numerous comparisons with p-values. Holm method was applied to address this 
issue. However, it must be taken into an account, that many of our outcome variables are 
interconnected due to the way they are calculated and they have also a strong clinical 
interconnection. Consideration is needed, when evaluating this statistical analysis. To our 
knowledge, this is the longest follow-up period in a probiotic allergy prevention trial with 
sensitisation analysis. The size of our cohort is still good 13 years after the intervention. 
 
Sensitisation analysis provided valuable information to accompany the questionnaire data. Increased 
sensitisation was observed in the probiotic group of the whole cohort, but not in the Caesarean-
delivered subgroup. On the basis of the results of our study, the development of sensitisation and 
that of allergic disease was surprisingly divergent. Probiotic treatment increased sensitisation and 
showed some tendency to result in less allergic disease in the whole cohort – and significant 
reduction in allergic disease was observed in a Caesarean-delivered subgroup. In a study by 
Kalliomäki et al.(17) a reduction in atopic eczema persisted at 7-year follow-up, but sensitisation was 
not reduced. It may be speculated, as has been proposed by Dotterud et al. (13), that the protective 
probiotic effect is not related to sensitisation, but may be related to an anti-inflammatory 
mechanism. The development of sensitisation is also different between different strains. In one 
cohort where L. acidophilus (LAVRI-A1) was used, the probiotic group had higher sensitisation 
compared to placebo group at 1-year-of-age. There was no difference in 2.5 years or at 5 years, 
which implies that L. acidophilus seems to prepone the development of sensitisation (26–28). In our 
cohort, colonisation of probiotic strains was observed at 6 months, but not anymore at 2 years of 
age (20). 
 
Beneficial findings were seen in the Caesarean-delivered subgroup, where the prevalence of eczema 
was 18.9% in the probiotic group and 37.5% in the placebo group. This is in line with previous results 
from our cohort. In the 5-year follow-up Caesarean-delivered children in the probiotic group had 
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significantly fewer IgE-associated allergies and less IgE-associated eczema (21). The prevalence of 
allergic diseases was very high in this high risk cohort (55.2% vs. 59.0%), which makes it convenient 
for observing possible preventative effects. However, the prevalence of allergic diseases was similar 
compared with that in another Finnish long-term follow-up study of high-risk cohorts (29), where 
the overall prevalence of allergic disease was 56.4% in probiotic groups and 46.6% in placebo 
groups. In one Norwegian perinatal prevention trial involving use of a probiotic mixture containing L. 
rhamnosus GG, L. acidophilus La-5 and B. animalis subsp. lactis Bb-12, an effect on atopic dermatitis 
was seen mainly in children with non-atopic parents but not in children with atopic parents (13). 
 
In previous literature, no significant differences have been found in lung-function measures, asthma 
or rhinitis in probiotic prevention trials (17–19). In our study we found fewer wheezing attacks in the 
probiotic group during the previous 12 months, but no effect on asthma prevalence. The same 
applies in a systematic review, where no protective association was found between perinatal use of 
probiotics and doctor-diagnosed asthma or childhood wheezing (30). 
 
The participation rate in the study (63.1%) was good considering the long follow-up period. At 5-year 
follow-up the participation rate was 87.5%. The demographic characteristics of the groups were 
similar. There was no difference in daily use of probiotics at 13 years, but weekly use was somewhat 
more common in the probiotic group. Most importantly, there was no difference in the use of (non-
study) probiotics during the early years (0–2 years) or at 3–5 years. It is believed that the microbiota 
and the immune system are most amenable to intervention by probiotics in the first year of life. 
Probiotics are already widely consumed, and the results of the trial could have possibly been more 
pronounced, without non-study probiotic usage. 
 
Probiotic products are commonly used, but regular daily use is rare in our population. In our study, 
probiotic treatment started before birth and continued for six months in infancy. Different timings 
and modes of administration (to breast-feeding mother or infant directly) have to be considered 
when further studying the matter. According to a review published in 2017, neither prenatal, 
postnatal nor pre- and postnatal treatment is consistently effective in different study designs (12). 
The strongest results, however, have been seen in studies with prenatal maternal administration 
and postnatal supplementation directly to the infant (11,20,31). In one prenatal study with 
Lactobacillus GG, no effect on eczema was found (32). The authors presented a strong argument 
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that probiotic treatment limited to the prenatal period is not effective for preventing eczema, or at 
least that Lactobacillus GG is not suitable for the purpose. In one study carried out in Sweden the 
treatment period lasted from 4–13 months of age, targeting the weaning period (19). In that study 
no long-term effect on any diagnosed allergic disease, airway inflammation or IgE sensitisation was 
found. 
 
The viability of the used probiotic product is important. In one treatment study stopped in the pilot 
phase, heat-inactivated LGG was associated with adverse gastrointestinal symptoms and diarrhoea. 
The viable LGG used by the comparison group in the same study showed a tendency to lead to a 
decrease in SCORAD scores (33). In our study and in the majority of all studies in this field a viable 
probiotic product has been used. In our cohort we also tested for the presence of the probiotic 
strains in the faeces of the participants at birth, and at three, six and 24 months of age (21). The 
prevalence of the probiotic bacteria was significantly higher in the probiotic group than in the 
placebo group at six months of age (20).  
 
World Allergy Organization guidelines (2015) suggest probiotics for pregnant women, breastfeeding 
women and for infants, when the child has a high risk for allergy. The benefit is considered to come 
mainly from preventing eczema (34). Pre- and postnatal probiotic intervention appears to be the 
most effective, and it has also been proposed that the question of the diversity of microbiota is 
multigenerational in wider sense. Correct selection of the probiotic strain is also important, and 
there is evidence concerning different effectiveness of the various probiotic strains. In a study with 
two treatment arms Lactobacillus rhamnosus HN001 was associated with a protective effect against 
eczema, but no effect was found as regards Bifidobacterium animalis subsp. lactis HN019 (31). 
 
In conclusion, probiotic treatment did not reduce the prevalence of allergic disease in the whole-
cohort in our 13-year follow-up study in a high-risk population. However, in the Caesarean-delivered 
subgroup, probiotics had a protective effect against any allergic disease and eczema, based on ISAAC 
questionnaire responses. Caesarean-delivered children appear to benefit more from affected 
maturation of the microbiota. It is quite commonly assumed, that the passage through birth canal is 
important in constituting the neonatal microbiome with the vaginal and stool bacteria, and 
therefore explains the caesarean delivered children’s higher risk for allergic diseases. This view has, 
though, been strongly criticised (35), and requires further investigation. Nevertheless, it is well 
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known that vaginally and caesarean delivered children have different microbiota composition during 
infancy (36). It is intriguing that the effect of early intervention is so strong that it is still detectable 
at the age of 13 years. The prevalence of allergic disease was high, and the consumption of non-
study probiotic products after the trial phase was common but irregular. Further investigation is 
needed to confirm the long-term effect of probiotic intervention in different populations and to 
identify the most effective probiotic strains, synbiotic combinations and timing of administration. 
 
We thank the study participants and their parents, and research nurse Rhea Paajanen and Nick 
Bolton for language editing. 
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Tables 
 
Table 1. Characteristics of the study children 
 
Probiotic Placebo 
n = 330 n = 312 
Female 50.3% 50.0% 
Birth weight (g, SD) 3588 (465) 3587 (503) 
Birth height (cm, SD) 50.6 (2.03) 50.5 (1.99) 
Mother’s age at labor (years) 31.1 31.6 
Maternal atopy 81.5% 81.1% 
Paternal atopy 57.9% 58.3% 
Both parents atopic 39.4% 39.4% 
Caesarean delivery 16.1% 17.9% 
Exclusive breast feeding >3 mo 53.0% 48.1% 
Exclusive breast feeding >5 mo 5.2% 2.6% 
Breast-feeding duration ≥6 mo 74.8% 68.3% 
Smoking at home (0–2 years) 27.9% 29.8% 
Smoking at home (13 years) 16.7% 18.3% 
Smoker (13 years) 0.6% 1.0% 
Dog/cat at home (0–2 years) 18.5% 17.9% 
Dog/cat at home (13 years) 38.5% 33.3% 
University-educated mother 33.3% 37.8% 
University-educated father 35.5% 37.2% 
Antibiotics during intervention 21.5% 27.9% 
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Table 2. Use of non-study probiotics 
 
Probiotic Placebo p (Pearson) p (Fisher) 
Early age     
Continuous 0–2 years 25.5% 25.0% .895 .928 
Continuous 3–5 years 29.1% 22.4% .054 .059 
Previous 3 years     
Used probiotics, any freq. 77.4% 76.0% .674 .709 
At 13 years 
    During antibiotic course 17.3% 16% .672 .751 
During diarrhoeal disease 12.7% 17.6% .083 .098 
At wintertime regularly 2.4% 2.2% .880 1.00 
Daily 9.7% 6.7% .172 .197 
Weekly 16.1% 10.6% .041 * .049 * 
Sometimes 48.2% 52.2% .304 .306 
In this table n (probiotic) = 330, n (placebo) = 312  
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Table 3. Allergic disease and sensitisation in the probiotic and placebo groups at 13 years 
  Probiotic % Placebo % OR 95% CI p (Pearson) p (Fisher) 
Primary endpoints               
Allergic disease  182/330 55.2  184/312 59.0 0.855 0.626 – 1.170 .328 .339 
Allergic disease, specific 
IgE >0.7 kU/L 
 105/246 42.7  85/213 39.9 1.121 0.722 – 1.628 .547 .569 
Secondary endpoints               
 Sensitisation               
Any specific IgE >0.7 kU/L  147/246 59.8  108/213 50.7 1.444 0.997 – 2.090 .052 .060 
Food-specific IgE >0.7 kU/L  53/246 21.5  41/213 19.2 1.152 0.730 – 1.819 .543 .564 
Inhalant-specific IgE >0.7 
kU/L 
 146/246 59.3  106/213 49.8 1.474 1.018 – 2.134 .040 * .048 * 
Any specific IgE >0.35 kU/L 158/246 64.2 124/213 58.2 1.289 0.884 – 1.879 .187 .211 
Food-specific IgE >0.35 
kU/L 
76/246 30.9 58/213 27.2 1.195 0.797 – 1.792 .389 .411 
Inhalant-specific IgE >0.35 
kU/L 
153/246 62.2 119/213 55.9 1.300 0.894 – 1.888 .169 .183 
 Allergic disease (doctor-
diagnosed, ever) 
              
Eczema all  105/330 31.8  111/312 35.6 0.845 0.609 – 1.173 .314 .317 
Eczema, IgE-associated *  61/246 24.8  55/213 25.8 0.947 0.621 – 1.444 .801 .830 
Asthma, all  42/330 12.7  53/312 17.0 0.713 0.460 – 1.105 .129 .148 
Asthma, IgE-associated *  25/246 10.2  26/213 12.2 0.814 0.454 – 1.457 .487 .552 
Rhinitis, IgE-associated †  76/246 30.9  59/213 27.7 1.167 0.779 – 1.748 .454 .473 
Food allergy  75/330 22.7  84/312 26.9 0.798 0.558 – 1.143 .218 .235 
Food allergy, IgE-
associated ‡ 
 25/246 10.2  26/213 12.2 0.814 0.454 – 1.457 .487 .552 
Allergic disease (ISAAC, 12 
months) 
              
Allergic disease  158/330 47.9  161/312 51.6 0.862 0.632 – 1.174 .346 .385 
Allergic disease, specific 
IgE >0.7 kU/L 
 103/246 41.9  80/213 37.6 1.197 0.823 – 1.743 .347 .390 
Eczema all  77/330 23.3  78/312 25.0 0.913 0.636 – 1.311 .622 .645 
Eczema, IgE-associated *  47/246 19.1  37/213 17.4 1.123 0.698 – 1.809 .632 .717 
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Values are presented as numbers and percentages of children. OR, unadjusted odds ratio. CI, confidence 
interval. 
* Any specific IgE level >0.7 kU/L 
† Any specific inhalant IgE level >0.7 kU/L 
‡ Any specific food IgE level >0.7 kU/L 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asthma, all  25/330 7.6  29/312 9.3 0.800 0.457 – 1.399 .433 .478 
Asthma, IgE-associated *  19/246 7.7  13/213 6.1 1.288 0.620 – 2.674 .497 .583 
Rhinitis, IgE-associated †  83/246 33.7  63/213 29.6 1.212 .816 – 1.801 .340 .366 
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Table 4. Allergic diseases and sensitisation in Caesarean-delivered children in the probiotic and 
placebo groups 
  Probiotic % Placebo % OR 95% CI p (Pearson) p (Fisher) 
Primary endpoints               
Allergic disease  34/53 64.2  37/56 66.1 0.919 0.418 – 2.021  .833  .844 
Allergic disease, specific IgE >0.7 
kU/L 
 15/38 39.5  20/40 50.0 0.652 0.266 – 1.602  .350 .372 
Secondary endpoints               
 Sensitisation               
Any specific IgE >0.7 kU/L  21/38 55.3  25/40 62.5 0.741 0.300 – 1.832  .516  .646 
Food-specific IgE >0.7 kU/L  9/38 23.7  9/40 22.5 1.069 0.373 – 3.066  .901  1.000 
Inhalant-specific IgE >0.7 kU/L  20/38 52.6  25/40 62.5 0.667 0.270 – 1.645  .378  .492 
Any specific IgE >0.35 kU/L 23/38 60.5 27/40 67.5 0.738 0.292 – 1.867 .521 .638 
Food-specific IgE >0.35 kU/L 12/38 31.6 13/40 32.5 0.959 0.370 – 2.483 .931 1.00 
Inhalant-specific IgE >0.35 kU/L 22/38 57.9 26/40 65.0 0.740 0.297 – 1.848 .519 .642 
 Allergic disease (doctor-
diagnosed, ever) 
              
Eczema all  24/53 45.3  23/56 41.1 1.187 0.556 – 2.536  .657  .702 
Eczema, IgE-associated *  11/38 28.9  12/40 30.0 0.951 0.359 – 2.518  .919  1.000 
Asthma, all  5/53 9.4  5/56 8.9 1.063 0.289 – 3.902  .927  1.000 
Asthma, IgE-associated *  3/38 7.9  2/40 5.0 1.629 0.257 – 10.328 .602 .671 
Rhinitis, IgE-associated †  8/38 21.1  14/40 35.0 0.495 0.179 – 1.367  .171  .212 
Food allergy  14/53 26.4  18/56 32.1 0.758 0.331 – 1.736  .512  .535 
Food allergy, IgE-associated ‡  3/38 7.9  6/40 15.0 0.486 0.112 – 2.100 .326 .482 
Allergic disease (ISAAC, 12 months)               
Allergic disease  22/53 41.5  38/56 67.9 0.336 .154 – 0.736  .006 *  .007 * 
Allergic disease, specific IgE >0.7 
kU/L 
 14/38 36.8  22/40 55.0 0.477 0.193 – 1.182 .108 .119 
Eczema all  10/53 18.9  21/56 37.5 0.388 0.162 – 0.930  .031 *  .036 * 
Eczema, IgE-associated *  6/38 15.8  12/40 30.0 0.438 0.145 – 1.319 .137 .181 
Asthma, all  2/53 3.8  3/56 5.4 0.693 0.111 – 4.319  .693  1.000 
Asthma, IgE-associated *  2/38 5.3  1/40 2.5 2.167 0.188 – 24.929 .526 .610 
Rhinitis, IgE-associated †  10/38 26.3  15/40 37.5 0.595 0.227 – 1.562  .290  .338 
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Values are presented as numbers and percentages of children. OR, unadjusted odds ratio. CI, confidence 
interval. Analysing the caesarean delivered subgroup was not part of the original study protocol. 
* Any specific IgE level >0.7 kU/L 
† Any specific inhalant IgE level >0.7 kU/L 
‡ Any specific food IgE level >0.7 kU/L 
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Table 5. Breakdown of asthma-related ISAAC questions 
 
 
 
 
In this table n (probiotic) = 330, n (placebo) = 31 
 
 
 
 
 
 
 
 
Probiotic % Placebo % OR (95% CI) p (Pearson) p (Fisher) 
Wheezing 
ever 116/330 35.2 122/312 39.1 0.844 (0.613 – 1.163) .300 .327 
Wheezing 
12 months 49/330 14.8 56/312 17.9 0.797 (0.524 – 1.212) .288 .337 
Wheezing 
attacks 
12months 28/330 8.5 46/312 14.7 0.536 (0.326 – 0.882) .013 * .014 * 
Night 
wheezing 
12 months 9/330 2.7 15/312 4.8 0.555 (0.239 – 1.288) .165 .212 
Limited 
speaking 12 
months 7/330 2.1 12/312 3.8 0.542 (0.211 – 1.394) .197 .246 
Asthma 
ever 51/330 15.5 57/312 18.3 0.818 (0.540 – 1.237) .341 .345 
Exercise 
wheezing 
12 months 42/330 12.7 44/312 14.1 0.888 (0.564 – 1.399) .609 .644 
Night cough 
12 months 46/330 13.9 60/312 19.2 0.680 (0.447 – 1.035) .071 .089 
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Chart 1. Flow chart of the study design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomisation (n=1223) 
Probiotic group mothers 
610 
Placebo group mothers 613 
Intention-to-treat infants 
506 
Intention-to-treat infants 
512 
2-year follow-up 461 2-year follow-up 464 
5-year follow-up 445 5-year follow-up 446 
10-year follow-up 407 10-year follow-up 400 
13-year follow-up 
questionnaire 330 
specific IgE 246 
13-year follow-up 
questionnaire 312 
specific IgE 213 
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Appendices 
Table 6. Characteristics of the study children in different subgroups 
 
Dropout 
group* 
Whole 
cohort (13y) 
Caesarean 
delivered 
(13y) 
Blood 
sample 
group (13y) 
n = 312 n= 642 n = 109 n = 459 
Female 51.6% 50.2% 50.5% 51.0% 
Birth weight (g, SD) 3606 (482) 3588 (484) 3592 (551) 3582 (478) 
Birth height (cm, SD) 50.6 (1.85) 50.6 (2.01) 50.3 (2.14) 50.5 (1.99) 
Mother’s age at labor (years) 30.5 31.3 32.6 31.5 
Maternal atopy 80.1% 81.3% 76.1% 81.7% 
Paternal atopy 59.3% 58.1% 57.8% 57.3% 
Both parents atopic 39.4% 39.4% 33.9% 39.0% 
Caesarean delivery 16.7% 17.0% - 17.0% 
Exclusive breast feeding >3 mo - 50.6% 42.2% 50.3% 
Exclusive breast feeding >5 mo - 3.9% 2.8% 3.9% 
Breast-feeding duration ≥6 mo - 71.7% 63.3% 71.7% 
Smoking at home (0–2 years) - 28.8% 31.2% 28.8% 
Smoking at home (13 years) - 17.4% 21.1% 16.3% 
Smoker (13 years) - 0.8% 1.8% 0.4% 
Dog/cat at home (0–2 years) - 18.2% 15.6% 17.9% 
Dog/cat at home (13 years) - 36.0% 39.4% 32.9% 
University-educated mother 36.2% 35.5% 31.2% 37.0% 
University-educated father 33.0% 36.3% 36.7% 37.3% 
Antibiotics during intervention 26.3% 24.6% 28.4% 23.1% 
* 64 infants from the dropout group had to be ignored due to missing data. 
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Table 7. Growth at 13 years 
  Probiotic SD Placebo SD 
Height (cm) 160.0 7.2 160.1 7.1 
Weight (kg) 49.5 9.75 49.2 9.65 
In this table n (probiotic) = 251, n (placebo) = 219 
 
 
Table 8. Essential haematological values at 13 years 
  Probiotic SD Placebo SD 
Leucocyte count 
(E9/L) 5.64 1.51 5.48 1.45 
RBC count 
(E12/L) 4.75 0.30 4.74 0.27 
Haemoglobin 
(g/L) 136.50 7.82 135.59 7.28 
Haematocrit (%) 39.95 2.16 39.67 1.92 
MCV (fl) 84.13 3.11 83.78 3.35 
RDW (%) 13.30 0.71 13.30 0.62 
MCH (pg) 28.83 1.19 28.67 1.28 
MCHC (g/L) 342.20 8.39 342.33 8.98 
Platelet count 
(E9/L) 260.96 52.23 266.92 49.80 
In this table n (probiotic) = 246, n (placebo) = 210 
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